Revue Francaise d Allergologie最新文献

{"title":"Asthme et usage du cannabis","authors":"I. Sajid,&nbsp;H. Arfaoui,&nbsp;N. Bougteb,&nbsp;H. Bamha,&nbsp;S. Msika,&nbsp;H. Jabri,&nbsp;W. El Khattabi,&nbsp;M.H. Afif","doi":"10.1016/j.reval.2026.104755","DOIUrl":"10.1016/j.reval.2026.104755","url":null,"abstract":"<div><h3>Prérequis/contexte</h3><div>L’asthme est un problème de santé publique aux retombées médicales, sociales et économiques importantes.</div><div>L’usage de cannabis peut être responsable de complications pulmonaires. Il peut être responsable de symptômes respiratoires (toux, sifflements thoraciques), favoriser le développement d’un asthme, augmenter le risque d’exacerbation aiguë d’asthme.</div></div><div><h3>Objectifs</h3><div>Le but de notre travail est de déterminer le profil de l’asthmatique cannabique et l’influence de ce dernier sur le contrôle de l’asthme.</div></div><div><h3>Méthodes</h3><div>Il s’agit d’une étude rétrospective, concernant les patients asthmatiques suivis en consultation d’allergologie dans notre service de juin 2018 à juin 2025. Au total, 44 patients ont été recrutés et répartis en 2 groupes : le groupe tabagique (GT) comprend 14 patients cannabiques, ex cannabiques avec un délai de sevrage allant de 1 à 6<!--> <!-->ans, ou exposés à un tabagisme passif (31,8 %). Le groupe non consommateur du cannabis (GNT) comprend 30 patients (68,2 %).</div></div><div><h3>Résultats/discussions</h3><div>La moyenne d’âge est de 39<!--> <!-->ans pour le groupe G.T et de 42<!--> <!-->ans pour le groupe G.NT. L’asthme est retrouvé chez 71 % du groupe T vs 51 % du groupe NT. Dans G.T, 54 % présentait un asthme sévère nécessitant un traitement pallier 5 contre 24 % seulement chez les asthmatiques non-fumeurs. L’asthme est non contrôlé chez 29 % des patients fumeurs vs 10,6 % des patients non-fumeurs avec comme facteurs de mauvais contrôle : la mauvaise observance du traitement, la mauvaise utilisation de l’inhalateur, une infection broncho-pulmonaire.</div></div><div><h3>Conclusion</h3><div>Tout praticien doit donc rechercher une consommation de tabac et de drogues en présence de symptômes pulmonaires et d’asthme surtout chez un sujet jeune et sain.</div></div>","PeriodicalId":49130,"journal":{"name":"Revue Francaise d Allergologie","volume":"66 ","pages":"Article 104755"},"PeriodicalIF":0.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147612511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of remibrutinib in anti-IgE biologic-naïve, biologic-experienced, and biologic-refractory patients with CSU: REMIX-1/-2 studies","authors":"F. Bérard ,&nbsp;S. Saini ,&nbsp;G. Mosnaim ,&nbsp;G. Sussman ,&nbsp;M. Metz ,&nbsp;S. Haemmerle ,&nbsp;K. Lheritier ,&nbsp;B. Yang ,&nbsp;N. Seko ,&nbsp;P. Wang ,&nbsp;A. Fukunaga","doi":"10.1016/j.reval.2026.104735","DOIUrl":"10.1016/j.reval.2026.104735","url":null,"abstract":"<div><h3>Prérequis/contexte</h3><div>Remibrutinib, an oral, highly selective Bruton's tyrosine kinase inhibitor, showed superiority in efficacy versus placebo and a favorable safety profile in patients with chronic spontaneous urticaria (CSU) who remained symptomatic despite treatment with second-generation H1-antihistamines (H1-AH) in REMIX-1/-2 phase 3 studies.</div></div><div><h3>Objectifs</h3><div>This pooled post hoc analysis of REMIX-1/-2 assessed the efficacy of remibrutinib in subgroups of patients analyzed by prior exposure to anti-immunoglobulin E (IgE) biologics.</div></div><div><h3>Méthodes</h3><div>REMIX-1/-2 were multicenter, randomized, double-blind, placebo-controlled studies assessing the efficacy and safety of oral remibrutinib 25<!--> <!-->mg twice daily (bid) in patients with CSU. Subgroups were analyzed by prior exposure to omalizumab, an anti-IgE biologic: no (naïve) and yes (experienced). Within the experienced subgroup, biologic-refractory patients experienced treatment discontinuation due to lack of efficacy, adverse events, or physician decision. Changes from baseline (CFB; mean<!--> <!-->±<!--> <!-->standard deviation) in weekly Urticaria Activity Score (UAS7), weekly Itch Severity Score (ISS7), and weekly Hives Severity Score (HSS7) at week 12 by subgroups were analyzed.</div></div><div><h3>Résultats/discussions</h3><div>At baseline, patients (remibrutinib [<em>n</em> <!-->=<!--> <!-->606] versus placebo [<em>n</em> <!-->=<!--> <!-->306]) had a high disease activity: UAS7 (30.6<!--> <!-->±<!--> <!-->7.8 vs 29.7<!--> <!-->±<!--> <!-->7.6), ISS7 (14.6<!--> <!-->±<!--> <!-->4.2 vs 14.1<!--> <!-->±<!--> <!-->4.0), and HSS7 (16.0<!--> <!-->±<!--> <!-->4.5 vs 15.6<!--> <!-->±<!--> <!-->4.5), respectively. At week 12, CFB-UAS7 with remibrutinib was similar and numerically high vs placebo across all subgroups (naïve: −21.4<!--> <!-->±<!--> <!-->11.2 vs −13.1<!--> <!-->±<!--> <!-->12.3; experienced: −21.0<!--> <!-->±<!--> <!-->13.3 vs −13.1<!--> <!-->±<!--> <!-->11.9; refractory: −22.1<!--> <!-->±<!--> <!-->13.5 vs −10.8<!--> <!-->±<!--> <!-->12.2). Similarly, remibrutinib showed comparable reductions in CFB-ISS7 and CFB-HSS7 across all subgroups.</div></div><div><h3>Conclusion</h3><div>Remibrutinib showed greater efficacy versus placebo, irrespective of prior exposure to and treatment failure with anti-IgE biologics, in patients with CSU.</div></div>","PeriodicalId":49130,"journal":{"name":"Revue Francaise d Allergologie","volume":"66 ","pages":"Article 104735"},"PeriodicalIF":0.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147612602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dermatite de contact chronique au Parthenium à l’ère du changement climatique : efficacité de l’azathioprine","authors":"Sofia Gueroum,&nbsp;Fatima-Zahra ElFatoiki,&nbsp;Fouzia Hali,&nbsp;Soumiya Chiheb","doi":"10.1016/j.reval.2025.104635","DOIUrl":"10.1016/j.reval.2025.104635","url":null,"abstract":"","PeriodicalId":49130,"journal":{"name":"Revue Francaise d Allergologie","volume":"66 2","pages":"Article 104635"},"PeriodicalIF":0.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145847535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact de l’intervention d’une conseillère en environnement intérieur à domicile, sur l’évolution de la santé des patients visités – étude rétrospective de onze ans de pratique (2011–2022)","authors":"M. Mesbah,&nbsp;S. Martinez,&nbsp;C. Gonzalez,&nbsp;N. Touati Leray","doi":"10.1016/j.reval.2025.104636","DOIUrl":"10.1016/j.reval.2025.104636","url":null,"abstract":"<div><div>An Indoor Environmental Advisor is a health professional trained to diagnose household environment of patients suffering from respiratory illnesses (mostly allergic asthma). They only intervene with a medical prescription. In order to evaluate the impact of the advisor's intervention on the patient's respiratory illness, a retrospective study was conducted from 2011 to 2022, over 648 house visits, through a form sent 6 months following the visit. In all, 164 forms were analyzed (25% of visited patients). The aim is to show the impact of these visits on the patient's health. Three out of four patients reported a global improvement in their health as well as a decrease in the number of attacks and crisis. For a quarter of patients, the ongoing disease treatment was stopped. Half of the patients are less absent (at work or school) and less often need to consult their physician or to be hospitalized. This declarative retrospective study contains biases but showcases a strong trend (namely health improvements, lower meds consumption, less hospitalizations) which are in agreement with those observed on numerous studies on the medical usefulness of the role of the Indoor Environment Advisor.</div></div>","PeriodicalId":49130,"journal":{"name":"Revue Francaise d Allergologie","volume":"66 2","pages":"Article 104636"},"PeriodicalIF":0.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145847707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cas clinique : anaphylaxie de grade 3 au propofol dès la 1re exposition ?","authors":"L. Durand ,&nbsp;E. Ewig ,&nbsp;B. Gerard ,&nbsp;G. Rezzadori ,&nbsp;F. Rocher ,&nbsp;S. Leroy ,&nbsp;M. Delin","doi":"10.1016/j.reval.2025.104642","DOIUrl":"10.1016/j.reval.2025.104642","url":null,"abstract":"<div><h3>Introduction</h3><div>Le propofol est un agent hypnotique intraveineux, couramment utilisé comme anesthésique dans l’induction et l’entretien des anesthésies générales. Les anaphylaxies périopératoires impliquent de nombreuses molécules mais l’imputabilité du propofol reste rare surtout dès la première exposition.</div></div><div><h3>Observation</h3><div>Un patient de 25 ans est opéré pour la première fois en septembre 2024 d’une septoturbinoplastie sous anesthésie générale. L’induction est réalisée par sufentanil, kétamine, propofol, et les traitements associés sont méthylprednisolone et lidocaïne. En peropératoire, le patient présente une anaphylaxie de grade 3. Les taux des tryptases percritiques étaient de 9,73<!--> <!-->μg/L à 30<!--> <!-->min et 12,3<!--> <!-->μg/L à 1<!--> <!-->h<!--> <!-->30 pour une tryptase basale à 2,94<!--> <!-->μg/L. Les tests cutanés réalisés 6 semaines plus tard étaient négatifs pour kétamine, propofol, sufentanil, lidocaïne, méthylprednisolone. Un test de provocation au propofol est réalisé, revenant positif au seuil de 1<!--> <!-->mg.</div></div><div><h3>Discussion</h3><div>Notre cas démontre une anaphylaxie IgE-médiée au propofol par le seul test de provocation et ceci lors d’une première exposition peropératoire. Les mécanismes de sensibilisation croisée restent rares mais possibles, notamment via les cosmétiques, ce que nous avons recherché chez notre patient, notamment par l’intermédiaire d’une crème visage dermatologique à laquelle il a réagi il y a plusieurs années.</div></div><div><h3>Conclusion</h3><div>Les anaphylaxies au propofol dès la première exposition peropératoire sont possibles. Ce cas souligne l’importance d’explorations exhaustives des anaphylaxies peropératoires, incluant, si nécessaire, la réalisation sécurisée de tests de provocation au propofol.</div></div>","PeriodicalId":49130,"journal":{"name":"Revue Francaise d Allergologie","volume":"66 2","pages":"Article 104642"},"PeriodicalIF":0.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146173181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mastocytose cutanée de l’enfant : étude de 15 cas","authors":"F. Elfatoiki,&nbsp;N. Chebbawi,&nbsp;F. Hali,&nbsp;S. Chiheb","doi":"10.1016/j.reval.2025.104638","DOIUrl":"10.1016/j.reval.2025.104638","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Introduction&lt;/h3&gt;&lt;div&gt;Les mastocytoses constituent un groupe de pathologies rares caractérisées par l’accumulation clonale de mastocytes dans divers tissus. Chez l’enfant, elles sont presque exclusivement limitées à la peau. Plusieurs formes cliniques sont décrites, la plus fréquente étant la mastocytose cutanée maculopapuleuse. L’évolution est généralement bénigne en pédiatrie.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Patients et méthodes&lt;/h3&gt;&lt;div&gt;Une étude rétrospective a été réalisée au sein du service de dermatologie du CHU Ibn Rochd de Casablanca entre janvier 2013 et décembre 2023. Elle a inclus tous les cas de mastocytose cutanée diagnostiqués chez des patients âgés de moins de 15 ans. Les données cliniques, biologiques, histologiques et les résultats thérapeutiques ont été analysés.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Résultats&lt;/h3&gt;&lt;div&gt;Quinze cas ont été colligés, dont neuf garçons et six filles. L’âge moyen au diagnostic était de 3 ans et 5 mois, avec un âge moyen de début des lésions estimé à 9 mois (extrêmes : 2 mois–2 ans). Des antécédents familiaux d’atopie ont été rapportés dans un cas. Tous les enfants présentaient une atteinte strictement cutanée. Le signe de Darier était présent chez six patients, un dermographisme chez trois, et un prurit chez trois également. La forme maculopapuleuse était la plus fréquente, observée chez 80 % des patients, tandis que 20 % des patients présentaient un mastocytome solitaire. La numération formule sanguine était normale chez tous les patients, et le taux moyen de tryptase sérique était de 6,5&lt;!--&gt; &lt;!--&gt;μg/L, avec des valeurs extrêmes comprises entre 3 et 10&lt;!--&gt; &lt;!--&gt;μg/L. Le diagnostic a été confirmé dans tous les cas par l’examen histologique et l’immunohistochimie, montrant un marquage positif des mastocytes pour le CD117 (c-KIT). Le traitement a consisté en l’administration d’antihistaminiques, avec adjonction de corticoïdes topiques uniquement en cas de turgescence afin de prévenir l’apparition de bulles. Le suivi moyen était de 6 ans (extrêmes : 2 à 10 ans). L’évolution a été marquée par une extension des lésions chez trois enfants (20 %), survenue dans les deux premières années suivant le début de la maladie, et une stabilité chez douze enfants (80 %).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Discussion&lt;/h3&gt;&lt;div&gt;Les résultats obtenus concordent avec les données de la littérature, mettant en évidence la prédominance des formes cutanées chez l’enfant, la fréquence des lésions maculopapuleuses, ainsi que le caractère généralement bénin de l’évolution clinique. Le diagnostic repose essentiellement sur la clinique, et la prise en charge est le plus souvent simple et symptomatique. Une régression spontanée est observée dans environ 80 % des cas, soulignant le bon pronostic global.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;div&gt;La mastocytose cutanée chez l’enfant présente en règle générale un bon pronostic, reste confinée à la peau dans la majorité des cas, et évolue vers une régression spontanée dans la plupart des situations. Néanmoins, un suivi p","PeriodicalId":49130,"journal":{"name":"Revue Francaise d Allergologie","volume":"66 2","pages":"Article 104638"},"PeriodicalIF":0.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146173182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"FPIES presenting as intussusception: A rare mimic or a triggered complication?","authors":"M. Özer","doi":"10.1016/j.reval.2025.104624","DOIUrl":"10.1016/j.reval.2025.104624","url":null,"abstract":"<div><h3>Introduction</h3><div>Food protein-induced enterocolitis syndrome (FPIES) is a rare form of non-IgE-mediated food allergy that typically presents in infancy. The clinical picture is usually characterized by delayed-onset, repetitive severe vomiting. Due to these symptoms, FPIES can be easily confused with acute abdominal conditions requiring surgical intervention, such as intussusception, and must therefore be considered in the differential diagnosis.</div></div><div><h3>Case report</h3><div>A previously healthy six-month-old male infant presented to the emergency department with profuse vomiting and lethargy approximately one hour after ingesting yogurt for the first time. Evaluation revealed intussusception, and surgical intervention was performed. Due to the history of recurrent vomiting and lethargy after yogurt ingestion, FPIES was considered as a preliminary diagnosis. At nine months of age, an open oral food challenge was performed, which confirmed the diagnosis of FPIES.</div></div><div><h3>Conclusion</h3><div>This case demonstrates that FPIES may not only mimic intussusception but also predispose to this complication. Therefore, FPIES should be considered in the differential diagnosis of infants presenting with gastrointestinal symptoms, and complications such as intussusception should be recognized as potentially associated with FPIES, particularly in cases of persistent vomiting despite ondansetron.</div></div>","PeriodicalId":49130,"journal":{"name":"Revue Francaise d Allergologie","volume":"66 2","pages":"Article 104624"},"PeriodicalIF":0.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145847758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact écologique des aérosols doseurs et autres dispositifs d’inhalation : l’arbre qui cache la forêt","authors":"A. Didier ,&nbsp;V. Heluain","doi":"10.1016/j.reval.2026.105001","DOIUrl":"10.1016/j.reval.2026.105001","url":null,"abstract":"","PeriodicalId":49130,"journal":{"name":"Revue Francaise d Allergologie","volume":"66 2","pages":"Article 105001"},"PeriodicalIF":0.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147395180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Désensibilisation au cotrimoxazole chez un nourrisson marocain atteint du syndrome de Wiskott-Aldrich : rapport de cas","authors":"M. Amaziane ,&nbsp;F. Makhloufi ,&nbsp;S. Benchekroun ,&nbsp;C. Mahraoui ,&nbsp;N. El Hafidi","doi":"10.1016/j.reval.2025.104637","DOIUrl":"10.1016/j.reval.2025.104637","url":null,"abstract":"<div><h3>Background</h3><div>Wiskott-Aldrich syndrome (WAS) is a rare primary immunodeficiency characterized by a classic triad of eczema, recurrent infections and microthrombocytopenia. Opportunistic infections are the leading cause of morbidity and mortality, underscoring the critical importance of cotrimoxazole (CMX) prophylaxis. However, CMX can cause cutaneous hypersensitivity reactions, which are particularly challenging in patients with WAS.</div></div><div><h3>Case presentation</h3><div>We describe the occurrence of an eczematous rash in an 11-month-old infant with WAS shortly after the initiation of CMX. Since the patient had also received intravenous immunoglobulin and antituberculous therapy, a comprehensive medication timeline was reconstructed in order to identify the causative agent. According to this analysis, the most likely trigger was CMX. In order to maintain prophylaxis, an oral desensitization protocol was subsequently implemented.</div></div><div><h3>Results</h3><div>Oral desensitization over three days was well tolerated, allowing full target daily dose administration without recurrence of cutaneous reaction and maintaining essential antibiotic prophylaxis.</div></div><div><h3>Conclusion</h3><div>Oral CMX desensitization is a safe and effective strategy in infants with WAS, for whom therapeutic alternatives are limited. Standardization and dissemination of pediatric desensitization protocols are necessary to improve patient care.</div></div>","PeriodicalId":49130,"journal":{"name":"Revue Francaise d Allergologie","volume":"66 1","pages":"Article 104637"},"PeriodicalIF":0.3,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145842246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Knowledge, practices and preparedness in anaphylaxis management among primary care physicians in Türkiye: A nationwide cross-sectional study","authors":"M. Yildiz ,&nbsp;A.C. Genc ,&nbsp;E. Zafer ,&nbsp;Ö. Özdemir","doi":"10.1016/j.reval.2025.104623","DOIUrl":"10.1016/j.reval.2025.104623","url":null,"abstract":"<div><h3>Study objective</h3><div>Anaphylaxis is a potentially life-threatening hypersensitivity reaction that requires prompt recognition and immediate intervention. Primary care physicians, often being the first to respond, play a critical role in its management; however, global evidence reveals persistent gaps in their knowledge and practice. This nationwide study aimed to assess the knowledge, clinical practices, and preparedness of primary care physicians in Turkey regarding the management of anaphylaxis.</div></div><div><h3>Methods</h3><div>A cross-sectional online survey was conducted among 400 active primary care physicians. The questionnaire comprised 8 demographic/practice items and 16 knowledge-based questions aligned with WAO 2020 and EAACI 2021 guidelines. Descriptive and multivariate statistical analyses were applied.</div></div><div><h3>Results</h3><div>While 86.5% of participants correctly identified epinephrine as the first-line treatment, only 74.0% knew the correct dose, 53.0% the appropriate concentration, and 78.8% the recommended injection site. Regular educational activity and recent training were significantly associated with higher knowledge scores (respectively; <em>P</em> <!-->=<!--> <!-->0.028 and <em>P</em> <!-->=<!--> <!-->0.021). Clinical experience alone did not predict better performance. Across all primary care physicians, the mean number of correct answers to the 16 knowledge-based questions was 9.93<!--> <!-->±<!--> <!-->2.48. Among subgroups, general practitioners scored significantly lower (8.82<!--> <!-->±<!--> <!-->2.60) compared to family medicine residents (10.02<!--> <!-->±<!--> <!-->2.36) and family medicine specialists (10.62<!--> <!-->±<!--> <!-->2.28) (<em>P</em> <!-->&lt;<!--> <!-->0.001).</div></div><div><h3>Conclusion</h3><div>The study reveals substantial knowledge deficiencies among Turkish primary care physicians, especially in epinephrine use (72%). Structured continuing education and integration of anaphylaxis-specific training into primary care physicians’ curricula are urgently needed to improve frontline response and patient safety.</div></div>","PeriodicalId":49130,"journal":{"name":"Revue Francaise d Allergologie","volume":"66 1","pages":"Article 104623"},"PeriodicalIF":0.3,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145792075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}